UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 or
15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of report
(Date of earliest event reported): May 26, 2017
Pharma-Bio Serv,
Inc.
(Exact Name of
Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
0-50956
|
20-0653570
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
6 Road 696, Dorado,
Puerto Rico
|
00646
|
(Address of
Principal Executive Offices)
|
(Zip
Code)
|
(787)
278-2709
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
(Former Name or
Former Address, if Changed Since Last Report)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
5.07. Submission of Matters to a Vote of Security
Holders.
On May 26, 2017,
Pharma-Bio Serv, Inc. (the “Company”) held its 2017
Annual Meeting of Stockholders. Below is a summary of the proposals
and corresponding votes.
Irving Wiesen was
elected as a Class I director to serve for a term until the 2020
Annual Meeting of Stockholders or until a successor is duly elected
and qualified. Irving Wiesen received the following
votes:
Nominee
|
|
For
|
|
Withheld
|
Irving
Wiesen
|
|
11,341,493
|
|
777,800
|
There were
4,211,404 broker non-votes on this proposal.
The ratification of
the selection of Horwath Velez & Co. PSC as the Company's
independent certified public accountants for the fiscal year ending
October 31, 2017 received the following votes:
For
|
|
Against
|
|
Abstain
|
16,282,897
|
|
47,800
|
|
-
|
There were no
broker non-votes on this proposal.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
PHARMA-BIO SERV,
INC.
|
|
|
|
|
|
|
Date: May 31,
2017
|
By:
|
/s/ Pedro J.
Lasanta
|
|
|
|
Pedro J.
Lasanta
|
|
|
|
Chief Financial
Officer, Vice President Finance and Administration and
Secretary
|
|
|
|
|
|
3